Net Product Sales was Neurocrine Biosciences’s largest product and service line in fiscal 2025, bringing in $2.83B of $2.86B (99%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingrezza | $1.40B | — | — | — | ||||||
| Net Product Sales | $1.44B | $1.86B | $2.33B | $2.83B | ||||||
| Product Sales, Net | — | — | — | — | ||||||
| Collaboration Revenues | — | $26.50M | $24.70M | $26.60M | ||||||
| Collaboration Revenue | $47.80M | — | — | — | ||||||
| Royalty | $21.20M | — | — | — | ||||||
| Total | $2.91B | $1.89B | $2.36B | $2.86B |
Neurocrine Biosciences brought in $2.86B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 21.4% from $2.36B in fiscal 2024. Net Product Sales was the largest at $2.83B (99.1%), ahead of Collaboration Revenues at $26.60M (0.9%).
Neurocrine Biosciences began breaking out Collaboration Revenues in fiscal 2023, when it brought in $26.50M. Neurocrine Biosciences stopped reporting Ingrezza ($1.40B in fiscal 2022), Collaboration Revenue ($47.80M in fiscal 2022) and Royalty ($21.20M in fiscal 2022) as separate lines.
Ingrezza Net Product Sales was Neurocrine Biosciences’s largest segment in fiscal 2025, bringing in $2.51B of $2.86B (88%).
| Segment | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Ingrezza Net Product Sales | $1.84B | $2.31B | $2.51B |
| Crenessity Net Product Sales | — | $1.70M | $301.20M |
| Other Revenues | $51.10M | $40.10M | $45.60M |
| Total | $1.89B | $2.36B | $2.86B |
Neurocrine Biosciences brought in $2.86B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 21.4% from $2.36B in fiscal 2024. Ingrezza Net Product Sales was the largest at $2.51B (87.9%), ahead of Crenessity Net Product Sales at $301.20M (10.5%) and Other Revenues at $45.60M (1.6%).
Compared with fiscal 2024, Crenessity Net Product Sales grew 17,617.6% to $301.20M and Ingrezza Net Product Sales grew 8.7% to $2.51B.
Neurocrine Biosciences began breaking out Crenessity Net Product Sales in fiscal 2024, when it brought in $1.70M.
Abbvie Inc was Neurocrine Biosciences’s largest revenue line in fiscal 2022, bringing in $21.20M of $41.20M (51%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2022 |
|---|---|
| Abbvie Inc | $21.20M |
| Mtpc | $20.00M |
| Total | $41.20M |
Neurocrine Biosciences brought in $41.20M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. Abbvie Inc was the largest at $21.20M (51.5%), ahead of Mtpc at $20.00M (48.5%).
Neurocrine Biosciences (NBIX) reports its revenue by product and service, by segment and by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, Net Product Sales was its largest product and service line, bringing in $2.83B (99.1% of the total), followed by Collaboration Revenues at $26.60M (0.9%).
Net Product Sales was Neurocrine Biosciences' largest product and service line in fiscal 2025, bringing in $2.83B, or 99.1% of the $2.86B total across its two product and service lines.
Ingrezza Net Product Sales was Neurocrine Biosciences' largest segment in fiscal 2025, bringing in $2.51B, or 87.9% of the $2.86B total across its three segments.
Abbvie Inc was Neurocrine Biosciences' largest revenue line in fiscal 2022, bringing in $21.20M, or 51.5% of the $41.20M total across its two revenue lines.
Crenessity Net Product Sales grew faster than Ingrezza Net Product Sales in fiscal 2025, up 17,617.6% from $1.70M to $301.20M. Ingrezza Net Product Sales grew 8.7% to $2.51B.
Every figure comes from Neurocrine Biosciences' annual financial filings, as reported. Each line keeps the name Neurocrine Biosciences gives it, and years follow its fiscal calendar.
Neurocrine Biosciences' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.